AU2025205635A1 — Edaravone suspension for oral administration

USPTO Abstract

#$%^&*AU2025205635A120250807.pdf##### ABSTRACT This invention provides with an edaravone suspension for oral administration having excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby. ABSTRACT This invention provides with an edaravone suspension for oral administration having excellent bioavailability. It is expected that burden on ALS patients and care workers can be reduced thereby. 20 25 20 56 35 21 J ul 2 02 5 A B S T R A C T T h i s i n v e n t i o n p r o v i d e s w i t h a n e d a r a v o n e s u s p e n s i o n f o r o r a l a d m i n i s t r a t i o n h a v i n g e x c e l l e n t 2 0 2 5 2 0 5 6 3 5 2 1 J u l 2 0 2 5 b i o a v a i l a b i l i t y . I t i s e x p e c t e d t h a t b u r d e n o n A L S p a t i e n t s a n d c a r e w o r k e r s c a n b e r e d u c e d t h e r e b y .